Choose Layout

Choose Color

November 2018

In November, again 52 transactions were recorded, aggregating to USD 1.8B, as in the previous month. Overwhelming dominance of US continued. Of the total investment, US garnered nearly 76% investment, amounting to USD 1392 M. ROW share was just around 10%, amounting to USD 197M. In the previous month, India recorded more value of deals compared to China. In India deal value was USD 124 M vis-à-vis USD 100 M. India recorded only 2 deals, as in the previous month, amounting to USD 124M – both in Digital Health.

- Team Wisdomsmith


In previous month, devices garnered highest share of 18% amount, closely followed by insurance / finance at 17%, and healthcare services at 16%. Other key therapies garnering good share was oncology (11%), bio-pharma (9%) and auto-immune (9%).

Top deals of November’18:

Leerink Partners is a leading investment bank, specializing in healthcare.

It’s knowledge, experience and focus enable it to help its clients define and achieve their strategic, capital markets and investment objectives. We partner with companies that develop and commercialize innovative products and services that are defining the future of healthcare.

Based in Silicon Valley, Auris Health is pioneering the next era of medical intervention by developing platforms that enhance physician capabilities, evolve minimally invasive techniques, and create new categories of care that redefine optimal patient outcomes.

The company is committed to transforming medical intervention by integrating robotics, micro-instrumentation, endoscope design, sensing, and data science into one platform. Every element of our technology is driven by patient-specific design aimed at maintaining the integrity of the human body.

Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops drugs for treating cholestatic liver diseases.

Post this funding, it has entered into an agreement with Shire for the exclusive global rights to develop and market maralixibat, an oral inhibitor of the apical sodium dependent bile acid transporter (ASBT). Shire will receive an upfront payment, an equity position in Mirum and potential future milestone payments and royalties. Maralixibat is being developed for Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC)

DKSH is the leading Market Expansion Services Group with a focus on Asia. It helps companies who are looking for a reliable outsourcing partner to grow their business in new or existing markets.

DKSH China offers a comprehensive package of services that includes organizing and running the entire value chain for any product: from sourcing, research and analysis, marketing, sales, distribution and logistics to after-sales services. We provide our partners with sound expertise, on-the-ground logistics and tailor-made services based on a comprehensive network of unique size and depth.

In the current funding, Warburg Pincus has bought the controlling stake in the company. The transaction includes DKSH’s pharma, consumer health and medical device businesses in China, while the group continues to hold its local business of consumer goods, performance materials and technology.

Alphamab Oncology raised this funding to advance a varied pipeline, which includes compounds in development for infertility, ophthalmology and infection, but the biotech has flagged oncology as its focus.

Alphamab lists 30 assets between its “innovation" and “biosimilar" pipelines on its website, with oncology treatments making up the bulk of its work. It has four programs in the clinic, including two bispecific antibodies, according to the statement: KN046, an antibody that targets PD-L1 and CTLA-4, and KN026, which targets HER2. Both are currently in phase 1—KN046 in Australia with multiple phase 1/2 trials to follow in China and KN026 in China, with a second phase 1 study coming up in the U.S.

The other two clinical-stage programs are KN035 (envafolimab), a PD-L1 antibody developed for subcutaneous delivery that is in pivotal trials in China, and KN019, an immunomodulator that is wrapping up phase 1. Alphamab expects to start a phase 2 trial of KN019 in the first half of next year.

Entero is focused on consolidating the pharma distribution in India, which is highly fragmented currently. It will use the funding to acquire mid-to-large size pharma distributors across key cities in India

NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases.

The proceeds will be primarily used to support clinical development for the company’s two lead drug candidates, including NC318, preclinical development of additional novel immunomedicine drug candidates, and the Company’s activities under its previously announced collaboration with Eli Lilly and Company to discover and develop novel cancer targets with the Company’s proprietary FIND-IO™ platform.

ViaCyte is a privately-held regenerative medicine company developing novel cell replacement therapies as potential long-term diabetes treatments that will reduce or eliminate the need for blood glucose monitoring, insulin administration, and the risks of hypoglycemia and diabetes-related complications.

ViaCyte has two products in clinical development. The first is called the PEC-Direct™ product candidate, which delivers proprietary pancreatic progenitor cells (PEC-01™ cells) in a non-immunoprotective device. The PEC-Direct product candidate is being developed for type 1 diabetes (T1D) patients who have hypoglycemia unawareness, recurrent severe hypoglycemic episodes, and/or extreme glycemic lability.

The second product is called the PEC-Encap™ (also known as VC-01) product candidate. The PEC-Encap product candidate delivers pancreatic progenitor cells in an immunoprotective device and is being developed as a potential therapy for all diabetes patients who use insulin to control their disease.

Koye Pharma is a pharma formulation company, primarily focused on the Indian market. It is one of the fastest growing company in India and one of the youngest company to enter the top 100 rankings

NIRAMAI has developed a novel breast cancer screening solution that uses Thermalytix, i.e. machine intelligence over thermography images. Its cloud hosted analytics solution uses big data analytics, artificial intelligence and machine learning algorithms for early & accurate breast cancer screening.